A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation

Inclusion Criteria: * Signed Informed Consent obtained before any trial-related procedures * Male or female age 18 to 70 years at the time of screening * Highly sensitized patients registered on the UNOS waiting list for kidney transplantation, with either of the following: * cPRA ≥ 99.9% * cPRA ≥ 98% and have been in kidney paired donation or kidney paired exchange programs for at least 1 year * A positive crossmatch towards a living donor * Willingness and ability to comply with the protocol Exclusion Criteria: * Previous treatment with imlifidase * Previous high dose IVIg treatment (2 g/kg) within 28 days prior to imlifidase treatment * Breast-feeding or pregnancy * Women of child-bearing potential not willing or able to practice FDA-approved forms of contraception. Two medically acceptable methods of highly effective contraception must be used for the duration of the study (e.g. oral, transdermal, intravaginal, injectable or implantable contraceptive; intrauterine device; intrauterine hormone-releasing system; vasectomized partner; bilateral tubal occlusion; or double-barrier method). For a woman to be considered postmenopausal this ascertainment must be made according to medical records and clinical history and may be aided by measurement of elevated postmenopausal serum gonadotropin levels (FSH). * ABO blood group incompatible transplantations (A2 and A2B kidneys will not be accepted for B recipients) * Positive serology for HIV * Clinical signs of HBV, HCV, CMV…